STOCK MARKET BSE NSE

Biocon inks patent litigation settlement pact with Celgene over bone marrow cancer medicine

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb.

Published: 08th September 2021 01:58 PM  |   Last Updated: 08th September 2021 01:58 PM   |  A+A-

Biocon MD Kiran Mazumdar-Shaw

Biocon MD Kiran Mazumdar-Shaw ( File Photo | EPS)

By PTI

NEW DELHI: Biotechnology major Biocon on Wednesday said it has entered into a settlement with Celgene Corporation regarding patents for Revlimid, a medication used to treat bone marrow cancer.

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing.

It did not share details of the agreement. Celgene had filed a complaint in the US, against Biocon for potential patent infringement. Biocon shares were trading 0.45 per cent up at Rs 358.30 apiece on BSE.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp